AngioDynamics spin-off nears completion
E-Z-EM announced Aug. 19 a common stock dividend of 9.2 million shares for its subsidiary AngioDynamics. The dividend, payable on Oct. 30 to E-Z-EM shareholders of record on Oct. 11, will mark AngioDynamics' debut as a separate company. The announcement
E-Z-EM announced Aug. 19 a common stock dividend of 9.2 million shares for its subsidiary AngioDynamics. The dividend, payable on Oct. 30 to E-Z-EM shareholders of record on Oct. 11, will mark AngioDynamics' debut as a separate company. The announcement came after E-Z-EM received a ruling from the IRS confirming that the dividend would be free from federal income taxes to E-Z-EM and its stockholders, except for any cash received by stockholders instead of a fractional share. AngioDynamics designs, develops, manufactures, and markets medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
